This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Petri, M. Search for Related Content PubMed PubMed Citation Articles by Petri, M. Social Bookmarking                   What's this?

Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis

Division of Molecular and Clinical Rheumatology, Johns Hopkins University School of Medicine, Suite 7500, 1830 E. Monument Street, Baltimore, MD 21205, USA

Hydroxychloroquine is used by 35% of SLE patients enrolled in the Baltimore Lupus Cohort. Eighty per cent of patients who took hydroxychloroquine at cohort entry remain on it six years later. In addition to its role for disease manifestations of lupus, hydroxy chloroquine may be indicated for the prevention of disease or treatment-induced com plications, including hyperlipidemia, diabetes mellitus, liver function test elevation and thrombosis.

Key Words: hydroxychloroquine • thrombosis • hyperlipidemia • diabetes mellitus • liver func tion tests

Lupus, Vol. 5, No. 1 suppl, S16-S22 (1996)
DOI: 10.1177/096120339600500105


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Kang, T. R Mikuls, and J. R O'Dell Hydroxychloroquine: a diabetic drug in disguise? BMJ Case Reports, March 2, 2009; 2009(mar01_1): bcr0820080654 - bcr0820080654. [Abstract] [Full Text]

				M. K. Farmer-Boatwright and R. A.S. Roubey Venous Thrombosis in the Antiphospholipid Syndrome Arterioscler. Thromb. Vasc. Biol., March 1, 2009; 29(3): 321 - 325. [Abstract] [Full Text] [PDF]

				R Kaiser, C M Cleveland, and L A Criswell Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort Ann Rheum Dis, February 1, 2009; 68(2): 238 - 241. [Abstract] [Full Text] [PDF]

				J. Sabio, M Zamora-Pasadas, J Jimenez-Jaimez, F Albadalejo, J Vargas-Hitos, M. Rodriguez del Aguila, C Hidalgo-Tenorio, M. Gonzalez-Gay, and J. Alonso Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain Lupus, September 1, 2008; 17(9): 849 - 859. [Abstract] [PDF]

				G Ruiz-Irastorza and M. Khamashta Hydroxychloroquine: the cornerstone of lupus therapy Lupus, April 1, 2008; 17(4): 271 - 273. [PDF]

				T. Avcin and E. Silverman Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome Lupus, August 1, 2007; 16(8): 627 - 633. [Abstract] [PDF]

				M. C. M. Wasko, H. B. Hubert, V. B. Lingala, J. R. Elliott, M. E. Luggen, J. F. Fries, and M. M. Ward Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis JAMA, July 11, 2007; 298(2): 187 - 193. [Abstract] [Full Text] [PDF]

				J.C. Sachet, E.F. Borba, E. Bonfa, C.G.C. Vinagre, V.M. Silva, and R.C. Maranhao Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients Lupus, April 1, 2007; 16(4): 273 - 278. [Abstract] [PDF]

				G Ruiz-Irastorza, M-V Egurbide, J-I Pijoan, M Garmendia, I Villar, A Martinez-Berriotxoa, J-G Erdozain, and C Aguirre Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus Lupus, September 1, 2006; 15(9): 577 - 583. [Abstract] [PDF]

				M L Bertolaccini and M A Khamashta Laboratory diagnosis and management challenges in the antiphospholipid syndrome Lupus, March 1, 2006; 15(3): 172 - 178. [Abstract] [PDF]

				D. H. Solomon, E. W. Karlson, E. B. Rimm, C. C. Cannuscio, L. A. Mandl, J. E. Manson, M. J. Stampfer, and G. C. Curhan Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis Circulation, March 11, 2003; 107(9): 1303 - 1307. [Abstract] [Full Text] [PDF]

				Y Molad, A Gorshtein, A J Wysenbeek, D Guedj, R Majadla, A Weinberger, and M Amit-Vazina Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort{ Lupus, June 1, 2002; 11(6): 356 - 361. [Abstract] [PDF]

				J. S. Levine, D. W. Branch, and J. Rauch The Antiphospholipid Syndrome N. Engl. J. Med., March 7, 2002; 346(10): 752 - 763. [Full Text] [PDF]

				A Wozniacka, A Carter, and D P Mccauliffe Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit Lupus, February 1, 2002; 11(2): 71 - 81. [Abstract] [PDF]

				D J Wallace Antimalarials--the 'real' advance in lupus Lupus, June 1, 2001; 10(6): 385 - 387. [PDF]

				R A Levy, V S Vilela, M J Cataldo, R C Ramos, J L. Duarte, B R Tura, E M. Albuquerque, and N R Jesus Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study Lupus, June 1, 2001; 10(6): 401 - 404. [Abstract] [PDF]

				D D'Cruz Antimalarial therapy: a panacea for mild lupus? Lupus, March 1, 2001; 10(3): 148 - 151. [Abstract] [PDF]

				M Petri Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort Lupus, March 1, 2000; 9(3): 170 - 175. [Abstract] [PDF]

				M. Petri Hydroxychloroquine: past, present, future Lupus, February 1, 1998; 7(2): 65 - 67. [PDF]